ERAP1,2 in Recalcitrant Warts

NCT06833164 | Completed

• 1 other identifier: Serum ERAP1 and 2 in warts
• Study Type: observational
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

The exact mechanisms underlying the contribution of cellular immunity in the eradication of human papillomavirus (HPV) infections remain obscure. Individuals who have treatment-resistant warts frequently have immune deficiencies. Amino-peptidases (ERAP1, ERAP2) of endoplasmic reticulum are essential for production of antigenic epitopes that attach to the Major Histocompatibility Complex (MHC) class I and activate T-lymphocytes or natural killer (NK) cells. Aim: To assess ERAP1 and ERAP2 serum concentrations in patients with resistant warts.

Conditions

Warts

Outcome Measures

Primary Outcomes (1)

• SERUM LEVELS OF endoplasmic reticulum aminopeptidase 1 and 2

  using specific Commercial human ELISA kits

  ONE YEAR

Interventions

endoplasmic reticulum Aminopeptidase 1 and 2 DIAGNOSTIC_TEST

endoplasmic reticulum aminopeptidase1 and 2 serum levels determination via ELISA

endoplasmic reticulum aminopeptidase 1 and 2 serum levels determination via ELISA DIAGNOSTIC_TEST

endoplasmic reticulum aminopeptidase 1 and 2 serum levels determination via ELISA

Also known as: SEUM ERAP1 MEASUREMENT USING ELISA, SERUM ERAP2MEASUREMENT USING ELISA

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Two hundred individuals were separated into two groups. Group (I) patients with resistant warts (n=100), and group (II) age- and sex-matched subjects with history of treated warts with no recurrence (n=100). They were recruited from the Dermatology Outpatient Clinic at Benha University Hospitals

You may qualify if:

• Patients who had a history of incomplete clearance or recurrence following two or more electrocautery sessions and four or more cryocautery treatments and intralesional bleomycin.

You may not qualify if:

• Patients with genital warts
• Patients on systemic steroids or other immunosuppressive treatments
• Immunocompromised individuals
• Patients suffering from chronic systemic diseases
• Pregnant women

Sponsors & Collaborators

• Benha University: lead

Study Sites (1)

faculty of medicine Benha University

Banhā, Qalyubia Governorate, 13511, Egypt

Location

MeSH Terms

Conditions

Warts

Condition Hierarchy (Ancestors)

Papillomavirus Infections; DNA Virus Infections; Virus Diseases; Infections; Skin Diseases, Viral; Tumor Virus Infections; Skin Diseases, Infectious; Skin Diseases; Skin and Connective Tissue Diseases

Study Officials

• Ihab Y. Abdallah, MD

  Professor of Dermatology, Venereology and Andrology, Faculty of Medicine, Benha University

  STUDY CHAIR

• Nehad A.Fouad, MD

  Professor of Microbiology and Immunology, Faculty of Medicine, Benha University

  STUDY DIRECTOR

• Ola S Ebrahim, MBBCh

  Benha University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Target Duration: 1 Day
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: assistant professor of dermatology, venereology and andrology

Study Record Dates

• First Submitted: February 13, 2025
• First Posted: February 18, 2025
• Study Start: October 1, 2022
• Primary Completion: March 20, 2024
• Study Completion: March 20, 2024
• Last Updated: February 18, 2025

Record last verified: 2025-02

Locations

EG (1)